DURECT Corporation Presenting at the CIBC World Markets Twelfth Annual Health Care Conference

Download PDF:

CUPERTINO, Calif., Nov. 1 /PRNewswire/ —
DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the
CIBC World Markets Twelfth Annual Health Care Conference. The conference is
taking place November 5-7 at The Plaza in New York City. Thomas A. Schreck,
Chief Financial Officer will be presenting at the conference on
Monday, November 5, 2001 at 10:00 a.m. EST.

The presentation will be webcast live from the Conference. The webcast
will be available on DURECT’s website at http://www.www.durect.com under the
Calendar of Events section of “Investor Relations.” The presentation will
also be available for replay on DURECT’s website for a period of 30 days after
the conference. To join DURECT’s email alert service and receive advance
notice of these and other events, please register by selecting “Email Alerts”
on the main Investor Relations web page at http://www.www.durect.com .

DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems for the treatment of chronic debilitating diseases and
enabling biotechnology-based pharmaceutical products. DURECT’s goal is to
deliver the right drug to the right site in the right amount at the right
time. DURECT’s pharmaceutical systems combine technology innovations from the
medical device and drug delivery industries with proprietary pharmaceutical
and biotechnology drug formulations. These capabilities can enable new drug
therapies or optimize existing therapies based on a broad range of compounds,
including small molecule pharmaceuticals as well as biotechnology molecules
such as proteins, peptides and genes. DURECT focuses on the treatment of
chronic diseases including pain, CNS disorders, cardiovascular disease and
cancer. DURECT holds an exclusive license from ALZA Corporation to develop
and commercialize products in selected fields based on the DUROS(R) implant
technology. Chronogesic(TM), a 3-month continuous infusion subcutaneous
implant for the treatment of chronic pain, is the first product in this series
and completed phase II testing in June, 2001. DURECT also owns
three proprietary erodible implant platform technologies, including SABER(TM)
(a patented and versatile depot injectable useful for protein delivery),
microspheres and drug-loaded implants. DURECT also commercializes IntraEAR(R)
catheters which have been used by physicians to treat inner ear disorders.

Founded in 1998, DURECT is headquartered in Cupertino, CA. The company’s
World Wide Web site can be accessed at http://www.www.durect.com . To join
DURECT’s email alert service, please register by selecting “Email Alerts” on
the main Investor Relations web page at http://www.www.durect.com .

NOTE: Chronogesic(TM), SABER(TM) and IntraEAR(R) are trademarks of DURECT
Corporation. DUROS(R) is a trademark of ALZA Corporation.

The statements in this press release regarding DURECT’s products in
development, product development plans, expected product benefits or potential
product markets are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. Potential risks and uncertainties
include, but are not limited to, DURECT’s ability to successfully complete
clinical trials, develop, manufacture and commercialize its products, obtain
product and manufacturing approvals from regulatory agencies, validate and
qualify a manufacturing facility and manage its growth and expenses, as well
as marketplace acceptance of DURECT’s products. Further information regarding
these and other risks is included in DURECT’s Quarterly Report on Form 10-Q
for the quarter ended June 30, 2001 filed with the SEC on August 14, 2001, and
Annual Report on Form 10-K for the fiscal year ended December 31, 2000 filed
with the SEC on March 30, 2001, under the heading “Factors that may effect
future results.”


CONTACT: Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or

Scroll to Top